DJIA 17,122.01 15.31 0.09%
NASDAQ 4,569.62 -1.02 -0.02%
S&P 500 2,000.12 0.10 0.00%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology

Vanda Pharmaceuticals, Prosensa, and Clovis Oncology could all loom large in health care headlines this morning. Here’s why.

Prosensa to Seek U.S. Approval for DMD Drug

Surprising MS Drug Approval: Time to Buy?

The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.

Is Prosensa Holding About to Soar?

Clinical-stage biotechs developing treatments for Duchenne muscular dystrophy have recently won a handful of political battles that have helped their drugs move forward on the regulatory front. Could Prosena be the next company to benefit from this change in political sentiment?

3 Stocks That Soared Stupendously Last Week

These 3 health-care stocks blew away the market this week. Here's how they did it.

Sarepta to Acquire Manufacturing Facility - Analyst Blog

Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Dru

Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Drug Approved

Sector Update: Healthcare

PTC Therapeutics Gets Warm Hug From Europe for DMD Drug; Prosensa Rises in Sympathy

Sector Update: Healthcare Shares Mixed; Vertex Up 6% on Positive Coverage

See More Articles...